Inhibition of pentagastrin-stimulated and overnight gastric secretion by LM24056, a new phenothiazine-derived antisecretory drug.
LM24056, a tricyclic drug, weakly inhibited pentagastrin-stimulated gastric secretion but was a powerful inhibitor of nocturnal gastric secretion in 5 healthy volunteers. In 23 patients with duodenal ulcer, LM24056 at doses of 100,200, and 300 mg inhibited overnight acid output by 31%, 70%, and 81%, and overnight pepsin secretion by 15%, 50%, and 69%, respectively. In view of its gastric inhibitory effects, LM24056 warrants clinical evaluation in the treatment of peptic ulcer disease.
D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D004381:Duodenal Ulcer / Q000188:drug therapy; D005750:Gastric Juice / Q000378:metabolism*; D006801:Humans; D010418:Pentagastrin / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D010434:Pepsin A / Q000378:metabolism; D010640:Phenothiazines / Q000494:pharmacology* / Q000627:therapeutic use; D011897:Random Allocation; D012636:Secretory Rate / Q000187:drug effects
D000897:Anti-Ulcer Agents; D010640:Phenothiazines; C028720:LM 24056; D010434:Pepsin A; D010418:Pentagastrin